NICE said it made every effort to support reimbursement for Kisunla and Leqembi, but found the medicines are “not good value ...

In a recent regulatory review, the Subject Expert Committee (SEC) under the Oncology division of the Central Drugs Standard ...

CNW/ - Eisai Limited, a leading research and development-based pharmaceutical company specializing in neurology and oncology, ...

And more pharma news updates from Pharmalittle.

Eisai and Biogen's drug, sold under the brand name Leqembi, is the first amyloid-targeting medication to pass the FDA's full review. Hotspots ranked Start the day smarter ...

Eisai is hoping to present enough evidence to the FDA to convince regulators that the benefit of treatment with lecanemab outweighs the risks and avoid a warning on the drug’s potential label.

Eisai and Biogen hope the long-term data, presented at the Alzheimer’s Association International Conference, will boost global adoption of Leqembi, which was approved by the Food and Drug ...

Ivan Cheung, chairman and CEO of Eisai Inc. When speaking to people living with Alzheimer’s disease and their loved ones, the first thing I tell them is that I am sorry it has taken so long to ...

MISSISSAUGA — Eisai Limited, a research and development-based pharmaceutical company specializing in neurology and oncology, has expanded the footprint of its Canadian headquarters in Mississauga, ...

Eisai Co. said a volunteer died while using the company’s experimental Alzheimer’s drug lecanemab in a clinical trial, but that it wasn’t clear if the death was directly caused by the drug ...

Japan's Eisai Co plans to seek full approval of its experimental Alzheimer's drug lecanemab in the United States, Europe and Japan armed with data showing it can slow the brain-wasting disease for ...

Eisai and Biogen sought the Food and Drug Administration’s accelerated approval for the amyloid beta-busting drug, lecanemab. Sold under the brand name Leqembi, the drug is priced at $26,500 per ...